Large-scale production of CD4+ T cells from HIV-1-infected donors after CD3/CD28 costimulation.

We describe a procedure for large-scale enrichment, growth, and harvesting CD4+ T cells. This method may be effective for HIV-1 immunotherapy, as the mode of stimulation, with anti-CD3 plus anti-CD28 coated beads (CD3/CD28 beads) induces a potent antiviral effect. PBMC were obtained by density gradient centrifugation of an apheresis product. Monocytes/macrophages were removed by incubating PBMC with beads coated with IgG. The cells were then magnetically depleted of B cells and CD8+ cells with mouse anti-CD20 and anti-CD8 MAbs and sheep antimouse coated beads. The remaining cells were >80% CD4+ and were transferred to gas-permeable bags containing CD3/CD28 beads and cultured in a closed system. After 14 days, the cell number increased an average of 37-fold, and cells were nearly 100% CD4+. Viral load, assessed by DNA PCR for HIV-1 gag, decreased >10-fold during culture in the absence of antiretroviral agents. Removal of CD3/CD28 beads from the cell suspension was accomplished by passing cells plus beads (3-30 x 10(9) cells in 2-12 L) over a MaxSep magnetic separator using gravity-driven flow. The cells were then concentrated to 300 ml in an automated centrifuge. This process allows safe and efficient growth of large numbers of CD4+ T cells from HIV-1+ donors.

[1]  T. Reynolds,et al.  T–cell mediated rejection of gene–modified HIV–specific cytotoxic T lymphocytes in HIV–infected patients , 1996, Nature Medicine.

[2]  D. Richman,et al.  Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. , 1997, Science.

[3]  S. Arya,et al.  Identification of RANTES, MIP-1α, and MIP-1β as the Major HIV-Suppressive Factors Produced by CD8+ T Cells , 1995, Science.

[4]  J. Lieberman,et al.  Safety of Autologous, Ex Vivo-Expanded Human Immunodeficiency Virus (HIV)-Specific Cytotoxic T-Lymphocyte Infusion in HIV-Infected Patients , 1997 .

[5]  Bruce L. Levine,et al.  Antiviral Effect and Ex Vivo CD4+ T Cell Proliferation in HIV-Positive Patients as a Result of CD28 Costimulation , 1996, Science.

[6]  G. Pantaleo.  How immune-based interventions can change HIV therapy , 1997, Nature Medicine.

[7]  S. Riddell,et al.  Phase I Study of Cellular Adoptive Immunotherapy Using Genetically Modified CD8+ HIV-Specific T Cells for HIV Seropositive Patients Undergoing Allogeneic Bone Marrow Transplant. Fred Hutchinson Cancer Research Center and the University of Washington , 1992 .

[8]  D. Scadden.  Immune reconstitution in AIDS: oncologic implications and hematologic approaches. , 1999, Current opinion in oncology.

[9]  S. Habu,et al.  Large-scale culture system of human CD4+ helper/killer T cells for the application to adoptive tumour immunotherapy. , 1992, British Journal of Cancer.

[10]  M. Fletcher,et al.  Clinical and immunological changes in AIDS patients following adoptive therapy with activated autologous CD8 T cells and interleukin‐2 infusion , 1994, AIDS.

[11]  E A Emini,et al.  Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. , 1997, The New England journal of medicine.

[12]  Anthony S. Fauci,et al.  Host factors and the pathogenesis of HIV-induced disease , 1996, Nature.

[13]  B. Levine,et al.  Intrinsic resistance to T cell infection with HIV type 1 induced by CD28 costimulation. , 1997, Journal of immunology.

[14]  M A Fischl,et al.  A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. , 1997, The New England journal of medicine.

[15]  S. Rosenberg,et al.  Development of an automated closed system for generation of human lymphokine-activated killer (LAK) cells for use in adoptive immunotherapy. , 1987, Journal of immunological methods.

[16]  S. Rowland-Jones,et al.  Control of HIV co-receptor expression: implications for pathogenesis and treatment. , 1997, Trends in microbiology.

[17]  R Brookmeyer,et al.  Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. , 1997, Science.

[18]  M A Nowak,et al.  Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[19]  S. Riddell,et al.  Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. , 1995, The New England journal of medicine.

[20]  M. Hirsch,et al.  Ex vivo expansion of CD4 lymphocytes from human immunodeficiency virus type 1-infected persons in the presence of combination antiretroviral agents. , 1995, The Journal of infectious diseases.

[21]  C. Vanhulle,et al.  Syngeneic adoptive transfer of anti-human immunodeficiency virus (HIV-1)-primed lymphocytes from a vaccinated HIV-seronegative individual to his HIV-1-infected identical twin. , 1994, Blood.

[22]  C. Verfaillie,et al.  Large scale ex vivo expansion and activation of human natural killer cells for autologous therapy. , 1994, Bone marrow transplantation.

[23]  E. Atkinson,et al.  Large-scale expansion in interleukin-2 of tumor-infiltrating lymphocytes from patients with ovarian carcinoma for adoptive immunotherapy. , 1994, Journal of immunological methods.

[24]  A. Gee,et al.  Design of large-scale separation systems for positive and negative immunomagnetic selection of cells using superparamagnetic microspheres. , 1992, Journal of hematotherapy.

[25]  A. Chang,et al.  Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. , 1985, The New England journal of medicine.

[26]  A. Nagler,et al.  Activated long-term peripheral blood cultures as preparation for adoptive alloreactive cell therapy in cancer patients. , 1997, Journal of hematotherapy.

[27]  T. Kakizoe,et al.  A feasible method for expansion of peripheral blood lymphocytes by culture with immobilized anti-CD3 monoclonal antibody and interleukin-2 for use in adoptive immunotherapy of cancer patients. , 1993, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[28]  H. Lane,et al.  A study of the safety and survival of the adoptive transfer of genetically marked syngeneic lymphocytes in HIV-infected identical twins. , 1993, Human gene therapy.

[29]  J Leibowitch,et al.  Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. , 1997, Science.

[30]  B. Levine,et al.  Differential regulation of HIV-1 fusion cofactor expression by CD28 costimulation of CD4+ T cells. , 1997, Science.

[31]  J. Yannelli.  The preparation of effector cells for use in the adoptive cellular immunotherapy of human cancer. , 1991, Journal of immunological methods.

[32]  R. Morgan,et al.  Efficient in vivo marking of primary CD4+ T lymphocytes in nonhuman primates using a gibbon ape leukemia virus-derived retroviral vector. , 1997, Blood.

[33]  B. Levine,et al.  CD28 ligands CD80 (B7-1) and CD86 (B7-2) induce long-term autocrine growth of CD4+ T cells and induce similar patterns of cytokine secretion in vitro. , 1995, International immunology.

[34]  C. Thompson,et al.  T-cell proliferation involving the CD28 pathway is associated with cyclosporine-resistant interleukin 2 gene expression , 1987, Molecular and cellular biology.

[35]  S. Rosenberg,et al.  Large scale production of human lymphokine activated killer cells for use in adoptive immunotherapy. , 1986, Journal of immunological methods.

[36]  D. Shah,et al.  A large-scale magnetic separator for selective cell separations with paramagnetic microbeads. , 1990, Artificial organs.